PGT’s business strategy is based on acquiring rights to prophylactic and therapeutic vaccine technologies that require commercial development, distribution and intellectual property protection and enhancement. The key roles for PGT are to align the technology with the set of partners that can finalize required technical development, provide access to the most needy markets and ensure that the intellectual property is robust and fully protected. In implementing its business strategy, PGT can bring to fruition new solutions to combat escalating infectious diseases in the most cost effective and time-sensitive manner.
PGT will continue to improve and enlarge its technology base and products through Isis and other acquired vaccine technologies that are the result of on-going collaborations with leading research organizations. PGT has a Sponsored Research Agreement with the University of Arkansas that is aimed at expanding the technology scope and application of Isis, as well as generating new platforms and intellectual property. PGT expects this collaboration will produce additional vaccine candidates for unmet needs in veterinary and human medicine. PGT will offer its vaccine candidates to vaccine and pharmaceutical industry participants to manufacture and distribute the products.
PGT’s approach to commercializing its products is to consider the best option for any given product and the markets for the product. Depending on the circumstances PGT’s approach to a market could be through a sub-license, joint venture or direct sales.
All information on this website has been copyrighted by the company Pacific Gene-Tech and this website is purely to promote and not to be beneficial in any manner. This information does not belong to me it belongs to the company of Pacific Gene-Tech.
